Artikelen door HollandBIO

Novel Public-Private collaboration for imaging method development

The European Infrastructure for Translational Medicine (EATRIS) has formed a collaboration with GlaxoSmithKline (GSK) to deliver a clinical and scientific expert network for the development and application of innovative imaging methods for inflammatory diseases. While existing clinical imaging tools provide useful endpoints in clinical trials, they typically lack sufficient cellular and molecular information to fully […]

Bright future ahead for organ- and lab-on-chip technology

On May 15th, MinacNed, hDMT and HollandBIO jointly organized the network meeting “Accelerating drug development using organ- & lab-on-a-chip technology”, mingling entrepreneurs with a background in biology and engineering. After three keynotes, two pitches and networking, the meeting’s take-home message was crystal clear: the fast-emerging field of organ- and lab-on-a-chip is of great value to […]

Subsidierondes Translationeel onderzoek geopend voor indiening

Binnen het programma Translationeel Onderzoek (PTO2) zijn 2 subsidie oproepen geopend. Indienen van een projectidee kan voor ‘Bench to bedside’ projecten en Multidisciplinaire consortia. Het doel van het programma is het versnellen van de overgang van preklinisch naar vroeg-klinisch onderzoek in de mens. Dit moeten ervoor zorgen dat kennis uit wetenschappelijk onderzoek eerder leidt tot […]

BiosparQ secures 3.4 million EUR

BiosparQ, has secured 3.4 million EUR in financing from the Dutch government. This funding comes in the form of an innovation credit, a loan from the government for innovation projects. BiosparQ. will be using this funding to accelerate the development, validation and certification of the DigiTOF platform for to the clinical market. DigiTOF BiosparQ is […]

Sanofi vestigt zich in Amsterdam

Sanofi, een wereldwijde leider op het gebied van gezondheidszorg, gaat in Nederland al zijn activiteiten en medewerkers huisvesten op één locatie in Amsterdam. Per november zullen ca. 200 medewerkers van Sanofi Gouda en 300 collega’s van de Nederlandse vestiging en het Europese hoofdkantoor van Sanofi Genzyme in Naarden hun intrek nemen in het Amsterdam Health […]

Janssen taking Legend CAR T therapy to clinic

Janssen said FDA cleared an IND for CAR T therapy JNJ-68284528 to treat multiple myeloma. Next half, the unit of Johnson & Johnson expects to start a U.S. and European Phase Ib/II study of Legend Biotech’s therapy targeting BCMA. At last year’s American Society of Clinical Oncology (ASCO) meeting, Legend reported JNJ-68284528 led to a […]

Filgotinib: Positive results

Gilead and Galapagos announced the successful completion of the phase 2 EQUATOR study of filgotinib, in patients with moderate to severe psoriatic arthritis. Concurrently, they announced the progression of SELECTION study  of filgotinib in patients with ulcerative colitis, to phase 3. Read the official press release here.

New at Pivot Park: GlycoMScan

GlycoMScan has opened their company’s doors in the van Leeuwenhoek building’s basement. GlycoMScan offers services in mass spectrometry, from screening of small molecules to absolute quantification in complex biological matrices. “As the name suggests, I am specialized in analyses of glycosylation and the building blocks thereof, the nucleotide sugars and phosphorylated sugars from intracellular metabolism,” […]

GM golden rice gets approval from food regulators in the US

GOLDEN rice, which has been genetically modified to prevent blindness in undernourished children, was judged safe to eat last week by the US Food and Drug Administration. The rice contains extra genes that make a precursor to vitamin A, which is vital for preventing childhood blindness. A single helping can supply half the recommended daily […]

Treeway prepares phase 3 study for TW001 to treat ALS

Phase 1 study suggests that novel oral formulation improves bioavailability while remaining well tolerated. Treeway, a biotech company developing therapies against amyotrophic lateral sclerosis (ALS), announced the completion of its Phase I trial of lead program TW001, an oral formulation of edaravone. The study compared the bioavailability of TW001 in its novel market formulation to […]